Forecast

The analysts' average price target is €1,068.09 (+39,458.89%). The median is €1,068.09 (+39,458.89%).

Buy	6
Hold	2
Sell	0

News Go to news feed

22nd Century Group: revenue rises, losses increase — stock falls premarket

22nd Century Group reported Q1 2026 revenue of $4.1 million (+16.1% vs. Q4 2025), but a larger operating loss of $3.0 million and a net loss up 7.1%. Gross loss narrowed to $0.6 million, yet Adjusted EBITDA remained negative at -$2.6 million. In premarket trading the stock plunged 18.43% to $0.694. Management is focusing on expanding distribution (target: >5,000 retail locations by end of 2026) and optimizing the product mix to improve profitability. » More on de.investing.com
22nd Century Group: revenue declining, quarterly loss per share $15.85

22nd Century Group reported a loss of $15.85 per share for the quarter ended 31 December 2025. Quarterly revenue fell 11.94% to $3.5 million (prior year: $4.0 million). For the full year the company reported revenue of $17.59 million, a decline of 27.85% from $24.38 million a year earlier, with an annual loss per share of $52.87. » More on finanzen.net
22nd Century Group announces 1-for-15 reverse stock split for January 26

22nd Century Group will implement a 1-for-15 reverse stock split on January 26, 2026 at 12:01 p.m. ET to regain Nasdaq Capital Market listing compliance. Fifteen issued common shares will be automatically converted into one share; fractional shares will not be issued and affected shareholders will instead receive a whole share. The number of outstanding shares will fall from 7,652,661 to approximately 510,177; a new CUSIP will be issued and options, warrants and preferred shares will be adjusted proportionally. The company reiterates its focus on VLN products, cost reductions, a completed restructuring and a request for an extension with the FDA for its nicotine-reduced cigarettes. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2019, 22nd Century Group Aktie has already paid €0.0721 in dividends. The last payout was in August 2019.

Financials

In the last quarter, 22nd Century Group Aktie had revenue of €2.51M and net profit of -€2.93M

(EUR)	Jun 2026	YoY
Revenue	2.51M	32.76%
Gross profit	-256.73K	52.35%
Net profit	-2.93M	1.43%
EBITDA	-2.66M	17.33%

Fundamentals

Metric	Value
Market capitalization	€905.55K
Number of shares	345.12K
52-week high/low	€558.00 - €2.59
Dividends	No
Beta	0.60
P/E ratio	-0.03
PEG ratio	0.00
P/B ratio	0.03
P/S ratio	0.11

Company profile

22nd Century Group, Inc. ist ein landwirtschaftliches Biotechnologieunternehmen, das sich auf die Reduzierung von Tabakschäden, nikotinreduzierten Tabak und die Verbesserung von Gesundheit und Wohlbefinden durch Pflanzenwissenschaften für die Life-Science- und Konsumgüterindustrie konzentriert. Das Unternehmen entwickelt Tabak- und Zigarettenprodukte mit sehr niedrigem Nikotingehalt unter den Namen VLN King und VLN Menthol King sowie SPECTRUM-Forschungszigaretten zur Verwendung in unabhängigen klinischen Studien. Das Unternehmen arbeitet mit Keygene N.V. zusammen, um Hanf-/Cannabispflanzen mit außergewöhnlichen Cannabinoidprofilen und anderen überlegenen agronomischen Merkmalen für medizinische, therapeutische und landwirtschaftliche Zwecke sowie für andere Anwendungen zu entwickeln. 22nd Century Group, Inc. wurde 1998 gegründet und hat seinen Hauptsitz in Buffalo, New York.